Handelsavisen
prelaunch
Companies Healthcare CLNP.WA
CL
CLNP.WA Warsaw Stock Exchange Pharmaceuticals

Clnp.Wa

$21,10
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-24,0 %
ROE
-21,5 %
Net margin
-32,1 %
Debt / equity
0,05
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

CLNP.WA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Business. CLNP.WA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
HOLD5 analysts
1 buy2 hold2 sell
Avg 12m price target18,57

Analyst recommendations

5 analysts · consensus Hold
Buy1
Hold2
Sell2
12-month price target
18,57
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
5 analysts · indicative
Ownership
not yet wired
Profitability
-21,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CLNP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CLNP.WA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    CLNP.WA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a low debt-to-equity ratio of 0.05, indicating a conservative leverage profile. However, the company reported negative free cash flow of -63.395 million PLN, which is a concern for liquidity and reinvestment capacity. The current ratio of 1.68 suggests the company has sufficient short-term assets to cover its short-term liabilities, but the negative operating income of -58.686 million PLN and net loss of -78.430 million PLN indicate operational challenges.

    Profitability metrics are significantly below industry norms, with a return on equity of -21.53% and a return on assets of -17.24%. These figures suggest the company is not generating returns that meet the cost of capital, which is a red flag for investors. The gross profit margin of 72.2% is relatively high, but the operating margin is negative, indicating high operating expenses or low pricing power.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to regional economic and regulatory risks. The absence of segment or geographic breakdown limits the ability to assess the company's exposure to different markets or product lines.

    The company's growth trajectory is uncertain, with no clear revenue growth or decline indicated in the available data. The negative operating income and net loss suggest a need for operational improvements or cost reductions to achieve profitability. The capital expenditure of -32.871 million PLN indicates ongoing investment, but the negative free cash flow suggests these investments are not yet generating positive returns.

    Risk factors include the company's negative net income and operating income, which could lead to liquidity constraints if not addressed. The low dilution risk is a positive, but the company's negative free cash flow and high operating expenses are potential red flags for future financial stability. No immediate filing-based liquidity or dilution flags were detected, but the company's financial performance suggests a need for close monitoring.

    Recent events include the publication of the latest financial data, which shows a net loss and negative operating income. No significant filings or transcripts were disclosed in the available data, but the company's financial performance indicates a need for strategic adjustments to improve profitability and cash flow.

    Key takeaways
    • CLNP.WA has a conservative capital structure with a low debt-to-equity ratio of 0.05.
    • The company is currently unprofitable, with a return on equity of -21.53% and a return on assets of -17.24%.
    • Revenue concentration in a single segment increases exposure to market-specific risks.
    • Negative free cash flow of -63.395 million PLN indicates liquidity and reinvestment challenges.
    • Analysts have a mixed outlook, with a mean price target of 18.57 PLN and a mean recommendation of 3.20.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $21,10
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $364.2M
    Net cash
    $351.0k
    Current ratio
    1.7
    Debt / equity
    0.1
    ROA
    -17.2%
    ROE
    -21.5%
    Cash conversion
    -28.0%
    CapEx / revenue
    -13.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution5 analysts
    Strong buy0
    Buy1
    Hold2
    Sell2
    Strong sell0
    12-month price target$18,57 · Median $18,00
    Low $16,00High $21,70
    Operating income · consensus-3,7M PLN
    Revenue surprise
    −12,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$16,00
    Mean$18,57
    Median$18,00
    High$21,70
    Spot$21,10
    −12.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-24,0 %Bottom quartile
    Net Margin-32,1 %Bottom quartile
    ROE-21,5 %Bottom quartile
    Capex / Rev-13,5 %Below median
    D/E0,05Above median
    Cash Conv-0,28Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • CLNP.WA Market data — financials · 2026-05-27
    • Celon Pharma SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Leadership

    • Robert Stanislaw RzeminskiChairman of the Supervisory Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CLNP.WACanonical
    Warsaw Stock Exchange · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage